Pharmaceutical development and manufacturing of a parenteral formulation of a novel antitumor agent, VNP40101M. - Wikidata - awgldk - TriplyDB

Pharmaceutical development and manufacturing of a parenteral formulation of a novel antitumor agent, VNP40101M.

Pharmaceutical development and manufacturing of a parenteral formulation of a novel antitumor agent, VNP40101M.

http://www.wikidata.org/entity/Q37360875

about

Solubility enhancement of Cox-2 inhibitors using various solvent systems Drug product development: a technical review of chemistry, manufacturing, and controls information for the support of pharmaceutical compound licensing activities.Targeting DNA polymerase ß for therapeutic intervention.Overview of drug product development.Composition optimization and stability testing of a parenteral antifungal solution based on a ternary solvent system.Transdermal delivery of cyclodextrin-solubilized curcumin.Pharmacokinetics, mass balance, and tissue distribution of a novel DNA alkylating agent, VNP40101M, in rat

P2860

Q34543254-FC1E7465-1420-4571-BE20-30EBF19481C7 Q35579328-BBAF01B8-4A29-4543-BD12-BB6C4CD38A49 Q37489149-0A2918B4-C295-4E50-AE98-A4843A8F6CC3 Q37965423-F29EA5B1-82EB-4C9D-8EAB-50FE90AA2DF2 Q39922873-AE6FF074-605E-438D-9D0B-2500AB4413A6 Q41195841-1DBA9993-8A9F-4E04-A2DC-221173C489A5 Q41876712-41196236-1B72-4468-8C9B-BCF626538B92

P2860

Pharmaceutical development and manufacturing of a parenteral formulation of a novel antitumor agent, VNP40101M.

http://www.wikidata.org/entity/Q37360875

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 August 2001

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Pharmaceutical development and ...... el antitumor agent, VNP40101M.

@en

Pharmaceutical development and ...... el antitumor agent, VNP40101M.

@nl

type

label

Pharmaceutical development and ...... el antitumor agent, VNP40101M.

@en

Pharmaceutical development and ...... el antitumor agent, VNP40101M.

@nl

prefLabel

Pharmaceutical development and ...... el antitumor agent, VNP40101M.

@en

Pharmaceutical development and ...... el antitumor agent, VNP40101M.

@nl

P1433

Q37360875-A07E56B7-74C3-4477-BAD7-1BD420BA6DFE

P1476

Q37360875-195CA6FC-7B65-4930-8874-528D48CAF879

P2093

Q37360875-38158A41-BBFD-4797-8340-7EA61B75C1ED

Q37360875-41D86C1D-524C-4FDC-ABAF-98AE934A270B

Q37360875-5CD84A70-6FB6-4AF8-BBBF-CF7F13B54035

Q37360875-A141351A-2977-483C-9AC4-35F03FC1A09E

Q37360875-ABFC115F-736D-49B2-ACDA-A4CEA33F3434

Q37360875-DB1BCC63-96E4-48F0-90E8-6B9E03CBAE18

Q37360875-E0097B09-AD2D-46AD-9272-BDB997618817

P2860

Q37360875-0912851F-145E-4130-9FB0-3998092F3C49

Q37360875-0D263F6F-23F5-437C-BEA4-593160DA7A51

Q37360875-2F182B68-EFAB-4198-AAA9-424970FEC033

Q37360875-62EDDE74-40B5-48AA-82CC-CF14FB66E089

Q37360875-7FF49850-319F-43B8-A49A-9006CDDEC0BE

Q37360875-8015636C-1A39-4441-9C04-02BC517CFC73

Q37360875-8C5F9089-659A-45CE-8789-9C423BB373D5

Q37360875-A1AC371A-C832-468F-AEF8-AE15D74B2386

P2888

Q37360875-26E403C9-A301-4EDE-BCE1-033C44DC7E1A

P304

Q37360875-010A0750-2947-4A58-934E-7B9A88C30760

P31

Q37360875-661A78F2-F3D2-46A0-92EF-121A72AF29C8

P356

Q37360875-5E5B1881-4580-41B1-BCDC-EA8A0B534FC0

P407

Q37360875-1BA2A5C1-06D4-43DE-A74B-425211596DEC

P433

Q37360875-2B591BC0-5EA6-4AF8-93A0-9E88BA2F05D8

P478

Q37360875-A211B364-1E7E-432D-89CC-6F9E8DD32095

P577

Q37360875-724E426A-2492-4726-A3AE-D80F0AE47572

P5875

Q37360875-F25E235F-2B82-4269-9EE7-F023EFAF74A4

P698

Q37360875-DAE81BEE-1DE6-4913-B645-FCC9860801CE

P932

Q37360875-D87535A0-AF7B-42CA-AC8A-98A2403A9A89

P356

P1433

AAPS PharmSciTech

P1476

Pharmaceutical development and ...... el antitumor agent, VNP40101M.

@en

P2093

B Almassian

http://www.w3.org/2001/XMLSchema#string

G Krishna

http://www.w3.org/2001/XMLSchema#string

J Mao

http://www.w3.org/2001/XMLSchema#string

S Karra

http://www.w3.org/2001/XMLSchema#string

W F Hodnick

http://www.w3.org/2001/XMLSchema#string

W Lang

http://www.w3.org/2001/XMLSchema#string

X Lin

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of DNA lesions produced by tumor-inhibitory 1,2-bis(sulfonyl)hydrazines and chloroethylnitrosoureas

Organic solvents for pharmaceutical parenterals and embolic liquids: a review of toxicity data.

Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells.

1,2-bis(arylsulfonyl)hydrazines. 2. The influence of arylsulfonyl and aralkylsulfonyl substituents on antitumor and alkylating activity.

1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine (101M): a novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity.

Compendium of excipients for parenteral formulations.

Synthesis and evaluation of 1-acyl-1,2-bis(methylsulfonyl)-2-(2- chloroethyl)hydrazines as antineoplastic agents.

Verapamil modulation of multidrug resistance in renal cell carcinoma.

P2888

P304

E14

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1208/PT020314

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2001-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8915745

http://www.w3.org/2001/XMLSchema#string

P698

14727873

http://www.w3.org/2001/XMLSchema#string

P932

2750579

http://www.w3.org/2001/XMLSchema#string